![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Spadel SA | EU:SPA | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.00 | -1.51% | 196.00 | 190.00 | 202.00 | 196.00 | 196.00 | 196.00 | 9 | 16:40:00 |
SR Pharma and Genesis Research Initiate Phase II Trial of AVAC(tm) in Childhood Eczema London and Auckland, 10 September 2003 - London-based biopharmaceutical company SR Pharma (LSE: SPA) and its partner Genesis Research and Development Corporation (NZX/ASX: GEN) today announce the start of a randomised, placebo-controlled phase II trial of AVAC(tm) in paediatric atopic dermatitis (childhood eczema). This trial, which aims to recruit 120 children aged from 5 to 16 years, is being conducted in Auckland, New Zealand. Each participating child will be randomised to one of two treatment groups and will receive 3 injections of either AVAC or placebo at intervals of 2 weeks. The trial will assess both the efficacy and safety of AVAC treatment. Quality of life data will also be collected. The New Zealand AVAC trial complements the phase II trial of SRP299 in childhood eczema, which is currently underway in the United Kingdom. SR Pharma and Genesis Research are jointly developing SRP299 and AVAC for the treatment of atopic dermatitis. The results of both the New Zealand and the UK phase II trials are expected to be available during the second half of 2004. Dr David Hill, CEO of SR Pharma, commented: "This new AVAC phase II trial follows on from the recent successful phase I AVAC safety trial conducted in children. In that trial, clinical improvement in atopic dermatitis was noted in the majority of the children as measured by a standard scoring system for eczema. The phase II trial will allow us to accurately assess the benefits resulting from AVAC treatment of children with eczema." About atopic dermatitis Atopic dermatitis, which is sometimes known as eczema, is a chronic disease in which the skin becomes itchy and inflamed. This causes redness, swelling, cracking, weeping, scaling and crusting. The prevalence of the disease has tripled in the past 30 years. Atopic dermatitis is estimated to affect 10-25% of children at some point during childhood and represents the commonest inflammatory skin disease in children. The prevalence in 7 year olds was recently reported as 16% in northern Europe and 23% in Singapore. 10-15% of children retain their childhood dermatitis into adulthood. The overall incidence in the UK has increased from 5% in 1946 to 12% in 1970. Over 60 million people suffer from atopic dermatitis in Europe and the USA. The disease is often associated with other allergic conditions and 40-50% of atopic dermatitis patients will also develop asthma and/or rhinitis. The global market size was estimated to be worth about £2 billion in 2000. About SR Pharma SR Pharma plc (www.srpharma.com) was founded in 1992 and is committed to developing innovative medicines based on an improved understanding of the role played by the immune system in combating disease. The company's proprietary M. vaccae-based technology is the source of a number of product developments. SRP299 is currently being evaluated for the treatment of asthma and atopic dermatitis. The company is also investigating SRL172 as both a monotherapy and as a vaccine adjuvant in cancer and infectious diseases. These products enhance the immune responses needed to combat cancer and infection, while regulating those that mediate allergies. For further information please contact: Steeve Lamontagne SR Pharma plc Tel : +44 (0) 20 7307 1628 Mobile: +44 (0) 7900 901 050 Email : s.lamontagne@srpharma.com SR Pharma and Genesis Research Initiate Phase II Trial of AVAC(tm) in Childhood Eczema Page 2 of 1 END
1 Year Spadel Chart |
1 Month Spadel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions